Oesophageal Varices

Abnormal, enlarged veins in the oesophagus

Aetiology

Portal Hypertension (Primary Cause)

Cause
Mechanism
Liver cirrhosis (most common)
Increased intrahepatic resistance
Portal vein thrombosis
Prehepatic obstruction
Budd–Chiari syndrome
Posthepatic obstruction
Schistosomiasis
Presinusoidal portal hypertension

Other (Less Common)

  • Non-cirrhotic portal fibrosis
  • Congenital hepatic fibrosis

Pathophysiology

  1. Chronic liver disease → increased portal venous pressure
  1. Formation of portosystemic collateral circulation
  1. Dilatation of submucosal veins in distal esophagus
  1. Thin-walled vessels exposed to trauma and pressure
  1. Rupture → acute upper GI bleeding
Clinically significant portal hypertension:
Hepatic venous pressure gradient (HVPG) ≥10 mmHg
Bleeding risk increases when HVPG ≥12 mmHg.

Clinical presentation

Asymptomatic
  • Most patients until bleeding occurs
Acute Variceal Bleeding (Medical Emergency)
  • Hematemesis
  • Melena
  • Hematochezia (massive bleed)
  • Hypovolemic shock
Associated Signs of Chronic Liver Disease
  • Jaundice
  • Ascites
  • Splenomegaly
  • Spider angiomas
  • Hepatic encephalopathy

Classification

By Size (Endoscopic)
Grade
Description
Small
Minimally elevated veins
Medium
Tortuous veins occupying <⅓ lumen
Large
Occupying >⅓ of lumen
High-Risk Stigmata (Endoscopic)
  • Red wale markings
  • Cherry red spots
  • Hematocystic spots
Red wale markings
Red wale markings
Cherry red spots
Cherry red spots

Investigations

  • Endoscopy

Management

Hemodynamic Stabilization

  • Crystalloid resuscitation
  • Restrictive transfusion strategy
    • Transfuse if Hb <7 g/dL → Target Hb 7–8 g/dL
  • Avoid over-transfusion (↑ portal pressure)

Primary Prophylaxis

Indications
  • Medium/large varices
  • Small varices with red wale signs
  • Decompensated cirrhosis
Options
  • Non-selective beta blockers (NSBBs)
    • NSBBs reduce portal pressure by ↓ cardiac output and splanchnic vasoconstriction.
      🚫 Do NOT start NSBBs during active bleeding or shock.
Drug
Starting Dose
Titration
Target
Notes
Propranolol
20 mg twice daily
Increase every 2–3 days
HR 55–60 bpm
Combine with EVL
Nadolol
20–40 mg once daily
Titrate as above
HR 55–60 bpm
Longer half-life
Carvedilol
6.25 mg once daily
Up to 12.5 mg/day
Tolerability
More BP lowering
  • Endoscopic variceal ligation (EVL)

Acute Variceal Bleeding (Rupture)

  • Resuscitation - maintain pulse and blood pressure, antibiotics
Drug
Dose
Route
Duration
Indication
Ceftriaxone
1 g 1x1
IV
5–7 days
First-line (advanced cirrhosis, high resistance)
Norfloxacin
400 mg 2x1
PO
5–7 days
Alternative if low resistance & stable
Ciprofloxacin
400 mg 2x1
IV
5–7 days
If ceftriaxone contraindicated
  • Vasoactive Agents
Drug
Loading Dose
Maintenance Dose
Duration
Key Notes
Terlipressin
2 mg IV bolus
1 mg IV every 4–6 h
2–5 days
↓ portal pressure; improves survival
Octreotide
50 µg IV bolus
50 µg/h IV infusion
2–5 days
Widely available; fewer ischemic effects
Somatostatin
250 µg IV bolus
250 µg/h IV infusion
2–5 days
Alternative to octreotide
  • Endoscopic variceal ligation (EVL)
  • Rescue / Bridge Therapy (If Uncontrolled Bleeding)
Therapy
Dose / Use
Duration
Notes
Balloon tamponade
As per device protocol
≤24 h
Temporary bridge to TIPS
TIPS
Definitive
For refractory bleeding or early TIPS candidates

Secondary prophylaxis

  • EVL
  • β- blockers